Decreased diabetes risk over 9 year after 18-month oral L-arginine treatment in middle-aged subjects with impaired glucose tolerance and metabolic syndrome (extension evaluation of L-arginine study).

Purpose: This study aimed to determine whether L-arginine supplementation lasting for 18 months maintained long-lasting effects on diabetes incidence, insulin secretion and sensitivity, oxidative stress, and endothelial function during 108 months among subjects at high risk of developing type 2 diab...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nutrition Vol. 57; no. 8; pp. 2805 - 2818
Autores principales: Monti, Lucilla D., Galluccio, Elena, Villa, Valentina, Fontana, Barbara, Spadoni, Serena, Piatti, Pier Marco
Formato: research Journal Article
Publicado: Springer Nature Dec2018
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=133123959&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 133123959
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14366207
        CR0
      jtl: European Journal of Nutrition
      issn: 14366207
      maglogo: N
    pubinfo:
      dt: Dec2018
      vid: 57
      iid: 8
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        133123959
        133123959
        133123959
        10.1007/s00394-017-1548-2
        133123959
      ppf: 2805
      ppct: 13
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Decreased diabetes risk over 9 year after 18-month oral L-arginine treatment in middle-aged subjects with impaired glucose tolerance and metabolic syndrome (extension evaluation of L-arginine study).
      aug:
        au:
          Monti, Lucilla D.
          Galluccio, Elena
          Villa, Valentina
          Fontana, Barbara
          Spadoni, Serena
          Piatti, Pier Marco
        affil: Cardio-Diabetes and Core Lab Unit, Department of Internal Medicine, Diabetes Research Institute, San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy
      sug:
        subj:
          Diabetes Mellitus, Type 2 Risk Factors
          Arginine Administration and Dosage
          Administration, Oral
          Glucose Intolerance
          Metabolic Syndrome X
          Dietary Supplementation
          Insulin
          Oxidative Stress
          Endothelium Physiology
          Pancreas Physiology
          Insulin Sensitivity
          Human
          Middle Age
          Incidence
          Diabetes Mellitus, Type 2 Diagnosis
          Proinsulin
          C-Peptide
          Homeostasis
          Consumer Participation
          Odds Ratio
          Confidence Intervals
          Middle Aged: 45-64 years
      ab: Purpose: This study aimed to determine whether L-arginine supplementation lasting for 18 months maintained long-lasting effects on diabetes incidence, insulin secretion and sensitivity, oxidative stress, and endothelial function during 108 months among subjects at high risk of developing type 2 diabetes.Methods: One hundred and forty-four middle-aged subjects with impaired glucose tolerance and metabolic syndrome were randomized in 2006 to an L-arginine supplementation (6.4 g orally/day) or placebo therapy lasting 18 months. This period was followed by a 90-month follow-up. The primary outcome was a diagnosis of diabetes during the 108 month study period. Secondary outcomes included changes in insulin secretion (proinsulin/c-peptide ratio), insulin sensitivity (IGI/HOMA-IR), oxidative stress (AOPPs), and vascular function. After the 18 month participation, subjects that were still free of diabetes and willing to continue their participation (104 subjects) were further followed until diabetes diagnosis, with a time span of about 9 years from baseline.Results: Although results derived from the 18 month of the intervention study demonstrated no differences in the probability of becoming diabetics, at the end of the study, the cumulative incidence of diabetes was of 40.6% in the L-arginine group and of 57.4% in the placebo group. The adjusted HR for diabetes (L-arginine vs. placebo) was 0.66; 95% CI 0.48, 0.91; p < 0.02). Proinsulin/c-peptide ratio (p < 0.001), IGI/HOMA-IR (p < 0.01), and AOPP (p < 0.05) levels were ameliorated in L-arginine compared to placebo.Conclusions: These results may suggest that the administration of L-arginine could delay the development of T2DM for a long period. This effect could be mediated, in some extent, by L-arginine-induced reduction in oxidative stress.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N